sinc
discoveri
decad
half
ago
genet
engin
dna
deliv
vaccin
form
elicit
immun
respons
much
progress
understand
basic
biolog
platform
larg
amount
data
gener
preclin
model
system
sustain
cellular
respons
consist
antibodi
respons
observ
clinic
four
dna
vaccin
product
recent
approv
area
veterinari
medicin
result
suggest
product
futur
technolog
optim
construct
better
trial
design
improv
platform
brought
clinic
dna
vaccin
burst
scientif
limelight
earli
tang
johnston
describ
deliveri
dna
skin
mice
use
gene
gun
attempt
deliv
human
growth
hormon
gene
therapi
author
felt
could
use
techniqu
gener
antibodi
respons
specif
transgen
product
time
three
present
annual
vaccin
meet
cold
spring
harbor
laboratori
report
use
dna
vector
drive
humor
cellular
immun
respons
pathogen
tumour
antigen
vivo
margaret
liu
colleagu
pharmaceut
compani
merck
report
inject
nake
plasmid
intramuscularli
deliv
immunogen
would
gener
immun
respons
influenza
viru
antigen
mice
similarli
robinson
describ
abil
dna
plasmid
drive
immun
respons
influenza
viru
antigen
present
weiner
describ
abil
plasmid
carri
hiv
antigen
tumour
antigen
produc
immun
respons
protect
tumour
challeng
mice
although
none
studi
use
deliveri
method
formul
plasmid
togeth
provid
evid
scientif
commun
simpl
techniqu
could
develop
immun
platform
past
decad
half
dna
vaccin
concept
test
appli
variou
pathogen
tumour
antigen
theori
conceptu
safe
nonliv
vaccin
approach
uniqu
technic
simpl
mean
induc
immun
respons
importantli
dna
vaccin
affect
humor
immun
also
cellular
immunityth
elus
target
live
infect
particular
dna
vaccin
induc
killer
cytotox
lymphocyt
ctl
suggest
import
shift
occur
nonliv
vaccin
platform
use
dna
approach
also
promis
overcom
safeti
concern
associ
live
vaccin
revers
risk
observ
subset
primat
receiv
live
attenu
simian
immunodefici
viru
siv
vaccin
potenti
spread
unintend
individu
addit
avoid
risk
link
manufactur
kill
vaccin
exemplifi
taint
polio
vaccin
live
polio
viru
owe
product
error
dna
vaccin
experienc
recent
resurg
interest
sever
technic
improv
contribut
achiev
includ
gene
optim
strategi
improv
rna
structur
design
novel
formul
immun
adjuv
effect
deliveri
approach
exampl
use
speciesspecif
codon
optim
result
increas
protein
product
percel
basi
lead
enhanc
tcell
respons
antibodi
induct
method
particularli
combin
caus
augment
level
immun
respons
rodent
well
larg
anim
model
importantli
recent
licens
four
veterinari
vaccin
product
hors
dog
pig
fish
serv
reenerg
field
hamper
poor
product
perform
larger
anim
model
nonhuman
primat
studi
human
clinic
trial
review
summar
statu
field
anim
human
clinic
trial
describ
import
platform
optim
strategi
improv
express
potenc
immunogen
also
highlight
creativ
strategi
import
technic
achiev
continu
drive
import
platform
dna
vaccin
produc
entic
result
wide
array
applic
prophylact
vaccin
strategi
target
viral
bacteri
parasit
infect
potenti
therapeut
use
treat
infecti
diseas
cancer
alzheim
diseas
allergi
autoimmun
disord
mechan
dna
vaccin
produc
antigenspecif
immun
vivo
intens
investig
ideal
model
present
box
optim
gene
sequenc
interest
deliv
skin
intraderm
subcutaneum
muscl
one
sever
deliveri
method
use
host
cellular
machineri
plasmid
enter
nucleu
transfect
local
cell
myocyt
keratinocyt
includ
resid
antigen
present
cell
apc
express
plasmidencod
gene
follow
gener
foreign
antigen
protein
convert
peptid
string
hostsynthes
antigen
becom
subject
immun
surveil
context
major
histocompat
complex
mhc
class
class
ii
molecul
apc
vaccin
host
antigenload
apc
travel
drain
lymph
node
present
antigen
peptidemhc
complex
combin
signal
costimulatori
molecul
naiv
cell
interact
provid
necessari
secondari
signal
initi
immun
respons
activ
expand
cell
altern
activ
b
cell
antibodi
product
cascad
togeth
humor
cellular
immun
respons
engend
prolifer
studi
small
anim
follow
initi
report
dna
vaccin
approach
focus
primarili
antibodi
induct
mice
includ
import
target
herp
simplex
viru
hepat
b
viru
hiv
influenza
viru
other
includ
virus
label
bioterrorist
agent
dna
platform
gener
great
deal
excit
preclin
protect
immun
induc
vaccin
broad
rang
viru
famili
exampl
applic
includ
strategi
target
rabi
viru
filoviru
flaviviru
togaviru
bunyanviru
well
bacteri
diseas
agent
anthrax
malaria
parasit
addit
owe
abil
dna
vaccin
drive
cellular
immun
cancer
immun
therapi
agent
target
includ
relev
melanoma
lymphoma
colon
prostat
breast
cancer
virus
bacteria
high
genet
divers
requir
ctl
defenc
infect
dna
platform
test
immun
therapi
differ
chronic
viral
infect
includ
human
papilloma
viru
hepat
c
viru
hiv
furthermor
ctl
induct
engend
dna
approach
seem
particularli
relev
variabl
pathogen
result
led
numer
dna
vaccin
clinic
trial
human
varieti
infecti
agent
cancer
well
immun
modul
strategi
treat
asthma
allergi
target
host
product
immunoglobulin
e
ige
addit
trial
test
abil
dna
vaccin
platform
deliv
gene
therapi
agent
treat
specif
chronic
ailment
first
dna
vaccin
studi
human
initi
almost
year
ago
limit
concept
high
optim
goal
variou
clinic
trial
demonstr
safeti
toler
candid
vaccin
explor
limit
immun
potenc
specif
dna
vaccin
human
tabl
earliest
phase
clinic
trial
dna
vaccin
candid
test
individu
infect
follow
studi
volunt
infect
prophylact
therapeut
dna
vaccin
trial
follow
includ
trial
test
dna
vaccin
cancer
influenza
malaria
hepat
b
candid
trial
demonstr
dna
vaccin
platform
well
toler
safe
advers
event
report
studi
went
complet
section
focu
result
two
main
applic
prophylact
vaccin
test
clinic
owe
wealth
studi
infecti
diseas
target
focu
class
first
includ
discuss
therapeut
vaccin
includ
cancer
therapi
merit
attent
owe
relev
studi
mani
diseas
involv
cell
prolifer
overal
firstgener
dna
vaccin
fail
demonstr
high
level
vaccinespecif
immun
human
although
learn
great
deal
safeti
deliveri
platform
howev
new
modif
improv
technolog
encourag
mani
current
recent
complet
trial
use
recombin
viral
vector
platform
dna
vaccin
combin
tradit
vectorbas
vaccin
immun
respons
prime
deliveri
dnaencod
antigen
boost
administr
recombin
protein
recombin
virus
socal
primeboost
strategi
preclin
anim
model
approach
increas
number
neutral
antibodi
also
boost
dnaprim
ctl
respons
optim
gene
sequenc
interest
exampl
antigen
immun
adjuv
gene
gener
synthet
pcr
sequenc
enzymat
insert
multipl
clone
region
plasmid
backbon
purifi
deliv
inocul
site
one
sever
deliveri
method
either
skin
subcutaneum
muscl
use
host
cellular
machineri
plasmid
enter
nucleu
transfect
myocyt
resid
antigen
present
cell
apc
plasmid
compon
initi
gene
transcript
follow
protein
product
cytoplasm
consequ
format
foreign
antigen
protein
peptid
string
cell
provid
endogen
posttransl
modif
antigen
reproduc
nativ
protein
conform
cell
custom
antigen
similar
manner
pathway
induc
live
infect
recombin
vector
hostsynthes
antigen
becom
subject
immun
surveil
context
major
histocompat
complex
class
mhc
mhc
ii
protein
vaccin
individu
apc
domin
role
induct
immun
dna
vaccin
present
vaccinederiv
endogen
peptid
mhc
molecul
follow
either
direct
transfect
plasmid
vaccin
crosspresent
cellassoci
exogen
antigen
exampl
owe
apc
engulf
apoptot
transfect
cell
addit
apc
mediat
display
peptid
mhc
ii
molecul
secret
protein
antigen
shed
transfect
cell
captur
process
within
endocyt
pathway
antigenload
apc
travel
drain
lymph
node
dln
via
affer
lymphat
vessel
present
peptid
antigen
naiv
cell
via
mhc
cell
receptor
tcr
combin
costimulatori
molecul
provid
necessari
secondari
signal
initi
immun
respons
expans
cell
respons
peptidebound
mhc
molecul
costimulatori
secondari
signal
activ
helper
cell
secret
cytokin
celltocel
interact
b
cell
bind
costimulatori
molecul
requir
b
cell
activ
addit
shed
antigen
captur
specif
high
affin
immunoglobulin
b
cell
receptor
bcl
express
surfac
b
cell
dln
present
process
antigen
helper
cell
therebi
facilit
induct
effect
b
cell
respons
theori
migrat
cell
prime
dln
could
restimul
expand
site
immun
present
peptidemhc
complex
display
transfect
muscl
cell
process
coordin
elicit
specif
immun
plasmidencod
antigen
activ
b
cell
arm
travel
effer
lymphat
system
provid
surveil
system
togeth
two
arm
immun
system
induc
specif
follow
dna
vaccin
creat
power
defenc
infecti
diseas
one
import
viral
vector
platform
modifi
vaccinia
viru
ankara
mva
geovax
use
mva
twoprong
primeboost
approach
dna
vaccin
contain
sever
hiv
antigen
prime
immunogen
follow
boost
recombin
mva
also
contain
hiv
antigen
combin
approach
well
toler
produc
detect
reproduc
cellular
immun
human
dna
prime
follow
mva
boost
also
studi
mcmichael
group
dna
vaccin
compos
string
dna
epitop
hiv
dna
fragment
encod
subtyp
hiv
gag
antigen
prime
immunogen
follow
mva
boost
contain
vaccin
antigen
howev
like
epitop
vaccin
deliv
differ
dna
approach
lowlevel
cell
respons
induc
vaccin
suggest
function
epitopebas
vaccin
human
warrant
studi
addit
novarti
laboratori
lu
univers
massachusett
explor
dnaplasmid
prime
follow
homolog
antigenicprotein
boost
human
studi
novarti
approach
use
dna
formul
polym
exampl
polylacticecoglycolid
boost
novel
trimer
envelop
protein
antigen
contrast
univers
massachusett
group
focus
multiplasmid
cocktail
multicocktail
envelopeprotein
boost
strategi
studi
shown
excel
safeti
record
strong
induct
antibodi
respons
well
cell
respons
limit
neutral
antibodi
respons
induc
studi
clearli
support
view
platform
combin
use
clinic
vaccin
target
cell
depend
howev
new
approach
lead
induct
potent
ctl
respons
continu
focu
studi
potent
recombin
vector
platform
human
gener
cellular
immun
seem
adenoviru
platform
viral
vector
gener
use
adenoviru
serotyp
potent
although
vector
base
new
promis
primat
serotyp
well
rare
human
serotyp
also
develop
much
work
vaccin
appli
vaccin
arena
import
studi
merck
vaccin
research
center
nation
institut
health
directli
compar
ctl
induct
gener
human
plasmid
vector
versu
recombin
vector
studi
show
plasmid
dna
least
four
time
less
potent
magnitud
respons
rate
vaccin
contain
similar
hiv
antigen
cassett
howev
recent
comparison
immun
respons
induc
viral
vector
approach
stop
merck
recent
vaccin
research
center
use
boost
approach
demonstr
littl
differ
immun
respons
elicit
two
vaccin
strategi
contrast
data
preclin
anim
model
test
studi
merck
illustr
need
improv
immun
potenc
dna
approach
prime
studi
lack
translat
anim
model
human
demonstr
need
continu
improv
deliveri
technolog
optim
import
primeboost
strategi
underscor
limit
nake
plasmid
approach
format
mani
cancer
antigen
excel
immun
therapi
target
dna
vaccin
cancer
vaccin
resembl
drug
therapi
readminist
regular
repetit
schedul
without
vector
interfer
concern
mous
model
dna
vaccin
success
direct
wide
varieti
tumour
almost
exclus
drive
strong
cellular
immun
respons
antigenspecif
fashion
furthermor
tumour
burden
decreas
even
obliter
novel
dna
vaccin
strategi
deliv
cytokin
plasmid
directli
tumour
cancer
immun
therapi
move
clinic
current
candid
well
toler
also
indic
immun
respons
patient
melanoma
prostat
cancer
case
suggest
clinic
benefit
report
basi
meet
clinic
endpoint
phase
ii
studi
vical
move
forward
phase
iii
studi
cytokin
deliveri
plasmid
formul
treat
melanoma
import
mileston
dna
vaccin
field
furthermor
studi
includ
use
electropor
deliv
antigen
cytokin
directli
tumour
give
interest
result
one
import
phase
clinic
trial
plasmid
dna
encod
potent
cytokin
deliv
directli
melanoma
lesion
follow
electropor
clinic
remiss
tumour
report
even
lesion
distant
inject
site
patient
use
helper
toxoid
link
cell
epitop
deliv
electropor
enhanc
immun
respons
prostat
cancer
also
promis
interest
newer
cancer
studi
target
viral
antigen
directli
new
approach
like
promot
growth
dna
cancer
immun
therapi
field
taken
togeth
select
trial
dna
vaccin
describ
shown
immun
respons
gener
human
also
highlight
need
increas
potenc
vaccin
technolog
effect
toward
end
crucial
analys
result
ongo
research
clinic
specif
pertain
success
failur
certain
design
deliveri
methodolog
nextgener
platform
addit
attent
success
licensur
dna
product
veterinari
arena
provid
use
inform
futur
human
clinic
studi
design
describ
detail
past
year
four
dna
product
licens
anim
use
one
west
nile
viru
hors
one
infecti
haematopoiet
necrosi
viru
school
salmon
one
treatment
melanoma
dog
recent
licensur
growth
hormon
releas
hormon
ghrh
product
foetal
loss
swine
tabl
licensur
import
valid
dna
vaccin
platform
illustr
commerci
potenti
moreov
success
product
show
dna
vaccin
manufactur
scale
low
cost
especi
case
fish
vaccin
infecti
haematopoiet
necrosi
viru
larg
anim
specif
circumst
success
protect
treat
specif
dna
vaccineapproach
approv
groundbreak
sever
respect
exampl
melanoma
vaccin
canin
melanoma
vaccin
first
licens
cellular
immun
therapi
cancer
ghrh
first
licens
gene
therapi
product
first
licens
electroporationdeliv
product
applic
could
argu
use
dna
anim
product
repres
easi
target
dna
vaccin
arena
compar
potenti
human
applic
exampl
antibodi
titr
induc
west
nile
viru
vaccin
hors
low
suggest
low
threshold
immun
protect
specif
pathogen
least
speci
howev
canin
melanoma
immun
therapi
model
system
clear
similar
human
diseas
electropor
deliveri
ghrh
pig
larg
speci
argu
differ
two
clinic
veterinari
success
suggest
adjust
product
might
give
rise
human
analogu
use
allevi
human
diseas
product
success
bode
well
sustain
growth
field
probabl
tip
iceberg
regard
practic
dna
vaccin
formul
product
anim
health
wherea
tradit
vaccin
reli
product
antibodi
inject
live
attenu
viru
kill
viral
particl
recombin
viral
protein
dna
vaccin
construct
function
mani
encod
safeti
featur
retain
specif
subunit
vaccin
dna
vaccin
plasmid
nonliv
nonrepl
nonspread
littl
risk
either
revers
diseasecaus
form
secondari
infect
addit
safeti
dna
vaccin
highli
flexibl
encod
sever
type
gene
includ
viral
bacteri
antigen
immunolog
biolog
protein
dna
vaccin
stabl
easili
store
manufactur
larg
scale
also
exampl
bypass
concern
adventiti
agent
might
transfer
tissuecultur
line
vaccin
individu
mani
potenti
advantag
dna
vaccin
summar
tabl
issu
rais
regard
safeti
dna
vaccin
includ
potenti
integr
cellular
dna
develop
autoimmun
possibl
antibiot
resist
dna
vaccin
current
test
show
relev
level
integr
host
cellular
dna
integr
detect
typic
occur
rate
order
magnitud
spontan
mutat
frequenc
howev
vector
modifi
adjuv
goal
increas
immunogen
could
increas
chanc
integr
concern
integr
vaccin
might
caus
insert
mutagenesi
activ
oncogen
inactiv
tumour
suppressor
gene
addit
integr
plasmid
dna
vaccin
could
theori
result
chromosom
instabl
induct
chromosom
break
rearrang
howev
none
concern
wit
preclin
clinic
evalu
dna
product
regard
develop
autoimmun
induc
dna
vaccin
preclin
studi
nonhuman
primat
earli
studi
human
detect
increas
antinuclear
antidna
antibodi
particip
human
trial
dna
vaccin
follow
possibl
sign
symptom
autoimmun
laboratori
marker
autoimmun
sometim
monitor
well
date
convinc
evid
autoimmun
develop
associ
dna
vaccin
third
issu
regard
dna
vaccin
involv
antibiot
resist
largescal
manufactur
dna
vaccin
involv
enrich
cultur
cell
plasmid
virtu
antibioticresist
marker
concern
rais
resist
antibiot
might
introduc
particip
transfer
carri
bacteria
plasmid
use
clinic
trial
howev
antibiot
resist
gene
contain
vaccin
plasmid
restrict
antibiot
particular
kanamycin
restrict
element
commonli
use
treat
human
infect
altern
strategi
use
antibiot
select
also
import
explor
respons
variou
safeti
concern
summar
tabl
european
union
us
food
drug
associ
fda
develop
specif
advic
safeti
test
dna
vaccin
effort
examin
integr
antibiot
resist
induct
autoimmun
follow
even
impress
unblemish
record
clinic
safeti
continu
expand
upon
base
outstand
safeti
record
focu
field
shift
optim
immun
induct
princip
issu
regard
futur
dna
vaccin
concern
improv
immunogen
larger
anim
human
dna
vaccin
platform
driven
significantli
weaker
immun
respons
nonhuman
primat
human
compar
mice
seem
less
immunogen
compar
recombin
viral
vector
adenovir
vector
recombin
protein
induct
antibodi
respons
howev
dna
vaccin
technolog
effort
ongo
optim
platform
increas
antigen
express
vaccin
immunogen
use
sever
strategi
discuss
shown
fig
sever
way
antigen
express
immunogen
improv
dna
vaccin
platform
includ
optim
transcript
element
plasmid
backbon
aim
improv
antigen
express
level
strategi
improv
protein
express
gene
interest
inclus
adjuv
formul
immun
modul
use
nextgener
deliveri
method
sever
laboratori
identifi
method
optim
transcript
element
plasmid
backbon
gene
transcript
express
improv
import
compon
plasmid
promot
drive
express
gene
interest
microbi
gene
promot
necessarili
optim
drive
optim
mammalian
gene
express
earli
studi
therefor
use
strong
promot
human
oncogen
virus
rou
sarcoma
viru
ref
howev
recent
promot
noncarcinogen
sourc
equal
effect
use
includ
one
human
cytomegaloviru
cmv
review
ref
vaccin
plasmid
human
cmv
promot
common
choic
promot
highlevel
constitut
express
wide
rang
mammalian
cell
suffer
downstream
readthrough
might
expect
strong
promot
altern
use
host
tissuespecif
promot
avoid
constitut
express
antigen
inappropri
tissu
exampl
use
promot
muscl
creatin
kinas
gene
lead
induct
antibodi
cell
respons
although
level
least
tenfold
lower
plasmid
contain
cmv
promot
data
suggest
use
hostcel
promot
limit
express
ultim
immunogen
might
advantag
gene
deliveri
moreov
promot
signific
homolog
hostcel
sequenc
might
need
optim
improv
human
clinic
outcom
second
import
modif
antigen
plasmid
inclus
termin
site
poli
signal
site
nucleotid
downstream
conserv
sequenc
aauaaa
end
mrna
signal
requir
proper
termin
transcript
export
mrna
nucleu
mani
dna
vaccin
use
bovin
growth
hormon
termin
sequenc
endogen
termin
downstream
orf
gene
interest
ensur
proper
transcript
termin
remain
seen
whether
modif
polyadenyl
termin
signal
influenc
gene
express
although
earli
report
promis
enhanc
element
transcript
transactiv
enhanc
promot
activ
place
either
upstream
downstream
orf
transactiv
gene
studi
viral
origin
exampl
regulatori
r
region
long
termin
repeat
ltr
human
tcell
leukaemia
viru
type
act
transcript
posttranscript
enhanc
result
cmvr
dna
vaccin
elicit
substanti
higher
specif
cellular
immun
respons
compar
analog
parent
dna
vaccin
mice
cynomolgu
monkey
howev
use
regulatori
enhanc
viral
origin
might
well
receiv
platform
owe
associ
oncogenesi
experiment
nonvir
transactiv
enhanc
element
dna
vaccin
plasmid
therefor
import
optim
regulatori
element
would
simpl
effect
strategi
augment
immunogen
dna
vaccin
mice
primat
studi
need
success
translat
strategi
clinic
use
higheffici
origin
bacteri
replic
relev
bacteri
strain
use
product
also
markedli
improv
quantiti
plasmid
product
one
strategi
use
improv
express
transgen
product
optim
initi
start
site
protein
synthesi
endogen
site
virus
bacteria
might
optim
express
mammalian
cell
modif
kozak
consensu
sequenc
focu
purpos
ensur
correct
termin
also
import
doubl
stopcodon
ad
prevent
read
could
lead
overs
incorrectli
fold
product
interfer
mrna
instabl
one
effect
way
increas
protein
product
use
codon
optim
immunogen
depend
effect
translat
transcript
antigen
protein
gene
express
greatli
increas
adopt
speciesspecif
codon
chang
procedur
result
increas
protein
product
lead
enhanc
cell
antibodi
respons
rna
optim
also
lead
effici
translat
sever
import
modif
includ
remov
instabl
element
lower
express
element
includ
secondari
mrna
structur
inhibit
ribosom
load
cryptic
sequenc
inhibit
nuclear
export
mrna
high
antigen
express
rate
prolong
mrna
stabil
crucial
heterolog
mammalian
express
import
gener
effect
dna
vaccin
addit
leader
sequenc
enhanc
stabil
mrna
contribut
translat
effici
exampl
signal
sequenc
envelop
glycoprotein
env
delay
cleavag
therefor
slow
rate
fold
insid
endoplasm
reticulum
mark
increas
protein
product
detect
nativ
env
leader
nativ
leader
encod
vacciniaexpress
mycobacterium
tuberculosi
antigen
replac
human
tissu
plasminogen
activ
leader
sequenc
enhanc
express
plasmid
antigen
also
observ
use
effici
leader
ige
gene
engin
vaccin
antigen
elicit
broadli
crossneutr
antibodi
challeng
particular
enhanc
immunogen
conserv
neutral
epitop
env
elimin
glycosyl
site
investig
treatment
increas
antibodi
titr
although
effect
structur
modif
neutral
phenotyp
clear
moreov
insert
proteolyt
cleavag
site
antigen
sequenc
gene
interest
gener
fuse
protein
peptid
might
import
ctl
process
similarli
recombin
protein
contain
fusogen
sequenc
provid
promis
system
induc
cytotox
cell
livevector
vaccin
destabil
phagosom
membran
epitop
reach
cytosol
recent
much
attent
focus
develop
consensu
immunogen
transgen
immun
owe
import
target
variabl
pathogen
sever
strategi
determin
consensu
sequenc
includ
analysi
ancestr
sequenc
well
advanc
method
epitop
scan
exampl
use
cell
assay
identifi
reactiv
epitop
predict
comput
analysi
softwar
phage
display
addit
use
dna
librari
protein
sequenc
data
target
epitop
abil
recogn
human
immun
system
use
identifi
novel
epitop
potenti
immunotherapi
target
virus
bacteria
parasit
tumourassoci
antigen
selfantigen
associ
pathogenesi
diseas
construct
drive
improv
crossreact
immun
respons
particularli
cell
level
mous
system
primat
human
studi
epitop
string
dna
vaccin
indic
approach
potent
whole
antigen
sequenc
howev
hope
potenc
strategi
improv
new
approach
link
epitop
inclus
helper
cell
sequenc
new
epitop
select
technolog
particularli
coupl
new
deliveri
strategi
cancer
model
exampl
tumourspecif
antigen
epitop
link
fragment
tetanu
toxoid
improv
helper
cell
respons
strategi
gener
strong
protect
immun
model
system
promis
clinic
approach
suppli
novel
cell
help
one
current
trend
dna
vaccin
formul
use
biodegrad
polymer
microparticl
review
ref
liposom
prospect
broad
applic
microparticlebas
liposomebas
deliveri
system
dna
vaccin
excel
util
deliveri
enhanc
immunogen
sever
differ
host
antigen
vaccin
platform
shown
mice
nonhuman
primat
human
plasmid
dna
trap
surfac
polym
exampl
polylacticecoglycolid
chitosan
deliv
system
directli
mucos
surfac
oral
via
respiratori
tract
complex
taken
denrit
cell
dc
result
upregul
dc
activ
marker
augment
system
mucos
immun
respons
exampl
import
molecul
move
forward
formul
adjuv
deliveri
method
dna
vaccin
includ
polyethyleneimin
aminefunction
polymethacryl
cation
poli
ester
poloxam
polyvinylpyrrolidon
polym
proven
success
diseas
model
exampl
deliveri
gene
therapeut
agent
cystic
fibrosi
poloaxm
success
preclin
model
simian
hiv
vaccin
strategi
importantli
vaxfectin
relat
molecul
enhanc
antibodi
respons
dna
vaccin
target
influenza
human
clinic
studi
type
formul
molecul
shown
signific
clinic
benefit
although
recent
data
vaxfectin
trial
perform
vi
cal
indic
clear
improv
immun
respons
human
result
trial
eagerli
await
addit
polym
ongo
studi
shown
liposom
vehicl
protect
dna
degrad
serum
protein
transfer
dna
across
membran
releas
genet
materi
follow
fusion
endosom
liposom
prepar
signific
structur
versatil
includ
vesicl
surfac
charg
cation
anion
liposom
made
size
lipid
content
codeliveri
adjuv
offer
consider
flexibl
toward
vaccin
optim
shown
induc
cellular
humor
immun
addit
optim
dna
antigen
plasmid
construct
separ
approach
includ
immun
modulatori
gene
cassett
part
plasmid
vaccin
cocktail
multipl
laboratori
report
coinject
plasmid
encod
cytokin
chemokin
costimulatori
molecul
substanti
effect
immun
respons
plasmidencod
antigen
includ
studi
multipl
viral
cancer
antigen
system
exampl
nonhuman
primat
potent
dna
vaccin
adjuv
cellular
immun
addit
mani
class
immun
modulatori
molecul
exist
target
death
receptor
growth
factor
adhes
molecul
cytokin
chemokin
well
tollreceptor
ligand
grow
number
immun
adjuv
formul
describ
use
individu
combin
maxim
effect
addit
synthet
oligodeoxynucleotid
contain
unmethyl
cpg
motif
act
immun
adjuv
mice
boost
humor
cellular
respons
coadminist
antigen
moreov
larg
number
ongo
preclin
studi
underscor
import
use
adjuv
owe
pleiotrop
effect
growth
differenti
matur
surviv
prolifer
mani
differ
cell
type
dna
vaccin
strategi
incorpor
immun
modulatori
formul
adjuv
improv
respons
clinic
prophylact
therapeut
studi
common
rout
immun
use
dna
vaccin
studi
intramuscular
rout
howev
sever
studi
demonstr
import
direct
transfect
apc
contrast
follow
intramuscular
immun
predomin
cell
type
transfect
dna
vaccin
myocyt
therefor
increas
transfect
effici
target
cell
variou
physic
deliveri
method
area
heavili
investig
recent
deliveri
method
includ
transcutan
microneedl
abil
bypass
stratum
corneum
layer
skin
thu
reach
langerhan
cell
apc
skin
review
ref
progress
microneedl
array
design
microneedl
applic
apparatu
formul
probabl
confirm
methodolog
realist
clinic
strategi
deliv
dna
skin
addit
use
lowfrequ
ultrasound
potent
physic
adjuv
success
transcutan
immun
develop
anoth
topic
applic
method
includ
paint
dna
vaccin
cytokineexpress
plasmid
onto
skin
mice
elimin
keratinocyt
layer
method
induc
mark
immun
respons
cellular
humor
env
protein
second
group
examin
novel
vaccin
hiv
call
dermavir
topic
administ
patch
contain
plasmid
dna
chemic
formul
nanoparticl
deliv
epiderm
langerhan
cell
interestingli
plasmid
dna
vector
make
approxim
trial
genetherapi
vector
platform
studi
phase
phase
iii
trial
see
figur
data
modifi
gene
therapi
trial
worldwid
provid
journal
gene
medicin
data
support
overal
preclin
success
phase
safeti
platform
platform
grow
steadili
dna
plasmid
vector
constitut
averag
genetherapi
platform
trial
shown
follow
unit
kingdom
germani
new
improv
particlemedi
epiderm
deliveri
pmed
technolog
vector
design
includ
coformul
pmed
dna
vaccin
adjuv
progress
enhanc
potenc
particlemedi
dna
vaccin
review
ref
effort
expect
acceler
commerci
pmed
effect
approach
vaccin
infecti
diseas
jetinject
mechan
devic
aim
deliv
protein
dna
vaccin
viabl
epidermi
thu
provid
potenti
safer
altern
needl
inject
method
promis
increas
efficaci
prevent
andor
therapi
infecti
diseas
allerg
disord
cancer
tattoo
perfor
needl
devic
bundl
fine
metal
needl
oscil
constant
high
frequenc
punctur
skin
lead
dna
transfer
skinassoci
cell
express
report
gene
mice
result
induct
cell
respons
recent
novel
approach
report
small
anim
target
epitopebas
dna
vaccin
dc
use
dctarget
ligand
crucial
determin
technolog
ultim
translat
clinic
among
impress
preclin
deliveri
strategi
electropor
techniqu
studi
two
decad
method
improv
deliveri
chemotherapi
drug
kill
specif
tumour
cell
electropor
extens
studi
larg
anim
speci
dog
pig
cattl
nonhuman
primat
deliv
therapeut
gene
encod
varieti
hormon
cytokin
enzym
antigen
vivo
express
level
improv
markedli
use
approach
level
increas
sever
fold
plasmid
inject
alon
method
might
allow
less
frequent
immun
dna
platform
improv
cellular
humor
respons
shown
mostli
smaller
anim
model
particular
tumour
system
howev
recent
studi
move
deliveri
strategi
nonhuman
primat
model
sever
differ
strategi
technolog
pursu
includ
deliv
electr
current
time
dna
inject
devic
use
constant
voltag
monitor
constant
current
devic
fit
penetr
probe
target
muscl
skin
strategi
use
callip
deliv
electr
puls
skin
howev
littl
current
known
sever
devic
much
addit
research
area
warrant
recent
sever
devic
move
clinic
evalu
result
eagerli
await
import
press
issu
includ
comparison
immun
respons
induc
strategi
best
recombin
viral
platform
toler
human
dna
vaccin
deliv
electrostimul
deliv
higher
bolu
antigen
produc
lower
dose
plasmid
conceptu
posit
safeti
aspect
technolog
well
addit
concern
aris
unfamiliar
technolog
human
strong
result
produc
approach
nonhuman
primat
larg
anim
includ
pig
hors
cattl
encourag
year
sinc
dna
vaccin
step
scientif
limelight
time
dna
vaccin
technolog
gener
great
deal
excit
well
disappoint
situat
howev
similar
develop
differ
breakthrough
technolog
platform
monoclon
antibodi
year
elaps
kohler
millstein
pioneer
report
hybridoma
technolog
commerci
first
human
therapeut
antibodi
product
new
technolog
seem
simpl
straightforward
illustr
review
decept
initi
idea
transform
workabl
platform
subtl
gradual
improv
regard
clear
sever
year
frustrat
dna
platform
back
product
path
fact
shown
box
dna
platform
repres
almost
one
quarter
gene
therapi
vector
system
clinic
evalu
opinion
strengthen
recent
licens
area
anim
health
improv
immun
potenc
report
nonhuman
primat
model
system
howev
next
year
clinic
test
new
complex
dna
vaccin
pivot
either
gener
true
clinic
success
base
immun
potenc
tell
us
still
much
go
previou
clinic
disappoint
highlight
likelihood
complex
dna
vaccin
design
includ
better
improv
formul
better
deliveri
technolog
enhanc
plasmid
deliveri
approach
judici
clinic
implement
stapl
continu
enhanc
platform
advanc
dna
platform
continu
excit
highli
product
adventur
illustr
best
academ
creativ
translat
scienc
success
built
high
level
cooper
industri
regulatori
author
fund
nongovernment
organ
public
academician
mixtur
one
activ
ingredi
made
safe
easi
store
transport
dilut
appli
presenc
materi
exampl
vehicl
solvent
ctl
also
known
c
tkiller
cell
killer
cell
belong
subgroup
lymphocyt
capabl
induc
death
infect
somat
tumour
cell
target
kill
cell
infect
pathogen
otherwis
damag
dysfunct
agent
stimul
immun
system
increas
respons
vaccin
without
specif
antigen
immun
respons
prefer
differ
organ
show
one
sever
codon
encod
particular
amino
acid
translat
optim
codon
recogn
abund
trna
within
phylogenet
group
frequenc
particular
codon
gene
highli
correl
higher
translat
rate
accuraci
layer
tissu
lie
surfac
skin
apc
special
cell
prime
naiv
cell
express
mhc
class
molecul
express
cell
prime
cytotox
cell
well
mhc
class
ii
molecul
prime
helper
cell
observ
readministr
bacteri
viral
vector
lead
reduct
potenc
occur
host
immun
respons
develop
neutral
antibodi
respons
vector
first
administ
dna
contain
protein
target
vector
interfer
loss
potenc
follow
dna
readministr
physic
process
expos
target
tissu
brief
electricfield
puls
order
induc
temporari
revers
pore
cell
membran
period
membran
destabil
molecul
plasmid
gain
intracellular
access
unknown
pathogen
present
cell
line
use
produc
vaccin
becom
part
final
vaccin
prepar
discov
way
contamin
poliovir
vaccin
dna
vaccin
produc
mammalian
cell
cultur
contain
agent
macaca
fasciculari
primarili
arbor
macaqu
nativ
southeast
asia
also
call
longtail
macaqu
specif
sequenc
occur
eukaryot
mrna
sequenc
recogn
requir
ribosom
translat
start
site
antibodi
recogn
wide
rang
antigen
epitop
immunogen
design
use
comput
analysi
code
dna
vaccin
synthes
gene
repres
common
amino
acid
posit
sequenc
base
popul
viral
isol
sequenc
method
use
bacteriophag
highthroughput
screen
protein
interact
protein
dna
peptid
made
bilay
membran
consist
polar
nonpolar
portion
phospholipid
form
multilay
shell
contain
charg
dnabind
region
dna
vaccin
technolog
target
ongo
effort
optim
platform
increas
antigen
express
vaccin
immunogen
see
main
text
detail
explan
step
current
sever
way
antigen
express
immunogen
improv
dna
vaccin
platform
includ
optim
transcript
element
plasmid
backbon
strategi
improv
protein
express
gene
interest
includ
factor
avoid
exampl
chisit
sequenc
encourag
crossingov
occur
site
inclus
formul
adjuv
immun
plasmid
adjuv
use
nextgener
deliveri
method
sever
formul
develop
test
stage
preclin
clinic
develop
abil
enhanc
antigen
express
immunogen
mechan
includ
encapsul
protect
dna
extracellular
degrad
particl
trap
highveloc
deliveri
ultim
goal
introduc
plasmid
directli
cytosol
target
cell
addit
immun
adjuv
class
encod
immun
modulatori
molecul
target
death
receptor
growth
factor
adhes
molecul
cytokin
chemokin
well
toll
receptor
ligand
exist
note
mani
plasmid
optim
formul
strategi
well
adjuv
system
use
combin
novel
deliveri
mechan
result
overal
enhanc
vaccin
platform
like
requir
cold
chain
immunogen
induct
antigenspecif
b
cell
respons
similar
elicit
live
attenu
platform
cold
chain
requir
keep
vaccin
chill
frozen
protect
potenc
degrad
room
temperatur
time
frame
manufactur
use
